Similar studies for GEO DataSets (Select 4278) - GEO DataSets

Links from GEO DataSets

Items: 20

Select item 42781.

Acute myeloid leukemia with CEBPA mutations [AMLSG cohort]: mononuclear cells

Analysis of mononuclear cells from bone marrow of untreated AML patients with CCAAT/enhancer binding protein alpha double mutation (CEBPAdm) or single mutation (CEBPAsm). Favorable outcome is observed in AML patients with CEBPAdm. Results provide insight into molecular basis of AML classification.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 5 disease state, 3 genotype/variation sets

Platform:: GPL570
Series:: GSE22845
154 Samples

Download data: CEL

DataSet

Accession:: GDS4278

ID:: 4278

Select item 2000228452.

Gene expression profiling of CEBPA double-, single-mutant and CEBPA wild type AML

(Submitter supplied) A previously predictive CEBPA double mutant (CEBPAdm) signature was hampered by the recently reported CEBPA silenced AML cases that carry a similar gene expression profile (GEP). Two independent AML cohorts were used to train and evaluate the predictive value of the CEBPAdm signature in terms of sensitivity and specificity. A predictive signature was created, containing 25-probe sets by using a logistic regression model with Lasso regularization, which selects discriminative probe sets between the classes, CEBPAdm and all other AML cases, CEBPA wild type (CEBPAwt) and CEBPA single mutant (CEBPAsm). more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4278
Platform:: GPL570
154 Samples

Download data: CEL

Series

Accession:: GSE22845

ID:: 200022845

Select item 2000144683.

Gene expression profiling of CEBPA double and single mutant and CEBPA wild type AML.

(Submitter supplied) Mutations in CCAAT/enhancer binding protein alpha (CEBPA) are seen in 5-14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry two mutations (CEBPAdouble-mut), usually biallelic, while single heterozygous mutations (CEBPAsingle-mut) are less frequently seen. Using denaturing high performance liquid chromatography and nucleotide sequencing we identified among a cohort of 598 newly diagnosed AMLs a subset of 41 CEBPA mutant cases, i.e. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
526 Samples

Download data: CEL

Series

Accession:: GSE14468

ID:: 200014468

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000152104.

Gene expression profiles of mono- and biallelic CEBPA mutations in cytogenetically normal AML

(Submitter supplied) Purpose: CEBPA mutations are found as either biallelic (biCEBPA) or monoallelic (moCEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic relevance in cytogenetically normal AML (CN-AML). Patients and Methods: 467 homogeneously treated CN-AML patients were subdivided into moCEBPA, biCEBPA and wildtype (wt) CEBPA patients. The subgroups were analyzed for clinical parameters and for additional mutations in the NPM1, FLT3 and MLL genes. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL8289
61 Samples

Download data: CEL

Series

Accession:: GSE15210

ID:: 200015210

Select item 2000420645.

Acute myeloid leukemia with CEBPA double-mutations harbors in 76.8% of cases concomitant molecular mutations with TET2 and GATA2 alterations demonstrating strong prognostic impact

(Submitter supplied) Acute myeloid leukemia (AML) with CEBPA mutations is determined as provisional entity in the current WHO. A difference in clinical outcome between single- (sm) and double-mutated (dm) cases has been reported, whereupon dm cases were shown to be associated with longer overall survival (OS). The occurrence and prognostic impact of concomitant molecular mutations in addition to CEBPAdm has not been assessed until now. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
38 Samples

Download data: CEL

Series

Accession:: GSE42064

ID:: 200042064

Select item 2000422026.

Detection of mutant NPM1 mRNA in acute myeloid leukemia (AML) using custom gene expression arrays

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Other

Platform:: GPL16267
648 Samples

Download data: CEL

Series

Accession:: GSE42202

ID:: 200042202

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000422007.

Detection of mutant NPM1 mRNA in acute myeloid leukemia (AML) using custom gene expression arrays [Validation cohort]

(Submitter supplied) Abstract Mutations in the gene encoding nucleophosmin (NPM1) carry prognostic value for patients with acute myeloid leukemia (AML). Various techniques are currently being used to detect these mutations in routine molecular diagnostics. Incorporation of accurate NPM1 mutation detection on a gene expression platform would enable simultaneous detection with various other expression biomarkers. Here we present an array based mutation detection using custom probes for NPM1 WT mRNA and NPM1 type A, B, and D mutant mRNA. more...

Organism:: Homo sapiens

Type:: Other

Platform:: GPL16267
143 Samples

Download data: CEL, TXT

Series

Accession:: GSE42200

ID:: 200042200

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000421948.

Detection of mutant NPM1 mRNA in acute myeloid leukemia (AML) using custom gene expression arrays [Training cohort]

Organism:: Homo sapiens

Type:: Other

Platform:: GPL16267
505 Samples

Download data: CEL, TXT

Series

Accession:: GSE42194

ID:: 200042194

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000332239.

Multilineage dysplasia does not influence prognosis in patients with CEBPA mutated AML supporting the WHO proposal to classify these patients as a unique entity

(Submitter supplied) By WHO 2008, CEBPA-mutated AML became a provisional subentity, but it remains to be clarified how CEBPAmut AML with multilineage dysplasia (MLD; ≥50% dysplastic cells in 2-3 lineages) but no other MDS-related feature should be classified. We investigated 108 CEBPAmut AML (15.7-87.6 years) for the impact of MLD and genetic features. MLD-positive patients differed from MLD-negative only by lower mean WBC counts (p=0.004), but not by other blood values, biologic characteristics, cytogenetic risk profiles, or additional molecular markers (NPM1mut, FLT3-ITD/TKD, RUNX1, MLL-PTD, IDH1/2). more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4407
Platform:: GPL570
30 Samples

Download data: CEL

Series

Accession:: GSE33223

ID:: 200033223

Select item 440710.

Biallelic CEBPA-mutated acute myeloid leukemia with multilineage dysplasia: peripheral blood mononuclear cells

Analysis of PBMCs from biallelic CEBPA (encoding CCAAT/enhancer binding protein)-mutated, acute myeloid leukemia (AML) patients with or without multilineage dysplasia (MLD). Cases without CEBPA mutations also examined. Results provide insight into the classification of CEBPA-mutated AML patients.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 3 disease state, 2 genotype/variation sets

Platform:: GPL570
Series:: GSE33223
30 Samples

Download data: CEL

DataSet

Accession:: GDS4407

ID:: 4407

Select item 20006364611.

Expression and Prognostic impact of LncRNAs in Acute Myeloid Leukemia

(Submitter supplied) Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides located within the intergenic stretches or overlapping antisense transcripts of protein coding genes. LncRNAs are involved in numerous biological roles including imprinting, epigenetic regulation, apoptosis and cell-cycle. To determine whether lncRNAs are associated with clinical features and recurrent mutations in older patients (aged ≥60 years) with cytogenetically normal (CN) acute myeloid leukemia (AML), we evaluated lncRNA expression in 148 untreated older CN-AML cases using a custom microarray platform.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL16791
71 Samples

Download data: XLS

Series

Accession:: GSE63646

ID:: 200063646

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20006361412.

Expression and Prognostic impact of LncRNAs in AML

Organism:: Homo sapiens

Type:: Expression profiling by array; Non-coding RNA profiling by array

Platform:: GPL16956
148 Samples

Download data: TXT

Series

Accession:: GSE63614

ID:: 200063614

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20016543013.

Gene Expression Signature Predicts Relapse in Adult Patients with Cytogenetically Normal Acute Myeloid Leukemia

(Submitter supplied) Although approximately 80% of adult patients with cytogenetically normal acute myeloid leukemia (CN-AML) achieve a complete remission (CR), over half of them relapse. Better identification of patients who are likely to relapse can help inform clinical decisions. We performed RNA sequencing on pretreatment samples from 268 adults with de novo CN-AML younger than 60 years who achieved a CR after induction treatment with standard “7+3” chemotherapy. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL20301
268 Samples

Download data: TXT

Series

Accession:: GSE165430

ID:: 200165430

PubMed Full text in PMC Similar studies

Select item 20021422414.

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by re-balancing GATA2 expression

(Submitter supplied) The myeloid transcription factor CEBPA is recurrently biallelically mutated (i.e., double mutated; CEBPADM) in acute myeloid leukemia (AML); with a combination of hypermorphic N-terminal mutations (CEBPANT), promoting expression of the leukemia-associated p30 isoform, and amorphic C-terminal mutations. CEBPADM AML features recurrent co‑occurring mutations; however, insight into the underlying mechanisms for the co-mutational spectra is incomplete. more...

Organism:: Mus musculus

Type:: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing

Platforms:: GPL30172 GPL21103
24 Samples

Download data: BED, BW, TXT, XLSX

Series

Accession:: GSE214224

ID:: 200214224

PubMed Full text in PMC Similar studies

Select item 20021386415.

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by rebalancing GATA2 expression

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing; Methylation profiling by high throughput sequencing

Platform:: GPL19057
11 Samples

Download data: TSV, TXT

Series

Accession:: GSE213864

ID:: 200213864

PubMed Full text in PMC Similar studies

Select item 20021386016.

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by rebalancing GATA2 expression [WGBS]

(Submitter supplied) The myeloid transcription factor CEBPA is recurrently biallelically mutated (i.e., double mutated; CEBPADM) in acute myeloid leukemia (AML) with a combination of hypermorphic N-terminal mutations (CEBPANT), promoting expression of the leukemia-associated p30 isoform, and amorphic C-terminal mutations. CEBPADM AML features recurrent co-occurring mutations including GATA2 lesions, however insights into mechanisms governing this co-mutational spectrum are incomplete. more...

Organism:: Mus musculus

Type:: Methylation profiling by high throughput sequencing

Platform:: GPL19057
5 Samples

Download data: TXT

Series

Accession:: GSE213860

ID:: 200213860

PubMed Full text in PMC Similar studies

Select item 20021382117.

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by rebalancing GATA2 expression [RNA-Seq]

Organism:: Mus musculus

Type:: Expression profiling by high throughput sequencing

Platform:: GPL19057
6 Samples

Download data: TSV

Series

Accession:: GSE213821

ID:: 200213821

PubMed Full text in PMC Similar studies

Select item 20015872718.

Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML

(Submitter supplied) We mapped p30-associated regulatory elements by ATAC-seq and ChIP-seq in a myeloid progenitor cell model for p30-driven AML that enables inducible RNAi-mediated knockdown of p30. Concomitant p30-dependent changes in gene expression were measured by RNA-seq. Integrative analysis identified 117 p30-dependent regulatory elements associated with 33 strongly down-regulated genes upon p30-knockdown.

Organism:: Mus musculus

Type:: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by high throughput sequencing

Platforms:: GPL21493 GPL17021
23 Samples

Download data: BW, TXT

Series

Accession:: GSE158727

ID:: 200158727

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20015382119.

The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes (ChIP-seq)

(Submitter supplied) Epigenetic regulators are frequently mutated in acute myeloid leukemia (AML). However, epigenetic dysregulation in AML extends beyond recurrently mutated factors and only little is known about the potential drivers in this context. Identification and characterization of novel epigenetic drivers impacting on AML biology will not only improve our basic understanding of AML but may also uncover novel options for therapeutic intervention. more...